BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 1382832)

  • 1. Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers.
    Wood DP; Herr HW; Motzer RJ; Reuter V; Sogani PC; Morse MJ; Bosl GJ
    Cancer; 1992 Nov; 70(9):2354-7. PubMed ID: 1382832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers.
    Habuchi T; Kamoto T; Hara I; Kawai K; Nakao M; Nonomura N; Kobayashi T; Ogawa O; Kamidono S; Akaza H; Okuyama A; Kato T; Miki T
    Cancer; 2003 Oct; 98(8):1635-42. PubMed ID: 14534879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chemotherapy-resistant germ cell cancer of the testis treated by salvage surgery: a case report].
    Taue R; Harada A; Katto K; Yamamoto Y; Kishimoto T; Nakatuji Y; Tanimoto S; Oka N; Izaki H; Fukumori T; Takahashi M; Nishitani M; Kanayama HO
    Hinyokika Kiyo; 2006 Apr; 52(4):293-6. PubMed ID: 16686359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of serum tumor markers in advanced germ cell tumors with responses to chemotherapy and surgery.
    Vugrin D; Friedman A; Whitmore WF
    Cancer; 1984 Mar; 53(6):1440-5. PubMed ID: 6198071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful 2-year-long remission following repeated salvage surgery in a patient with chemotherapy-resistant metastatic nonseminomatous germ cell tumor.
    Takeshita H; Yonese J; Fujii Y; Kawakami S; Komai Y; Ohkubo Y; Yamamoto S; Ishikawa Y; Seto Y; Ohyama S; Fukui I
    Int J Clin Oncol; 2007 Dec; 12(6):485-7. PubMed ID: 18071871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postchemotherapy Residual Tumor Resection in Patients with Elevated Tumor Markers.
    Che Y; Buddensieck C; Albers P; Lusch A; Winter C; Siemer RG; Hiester A
    J Urol; 2022 Mar; 207(3):617-626. PubMed ID: 34694152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
    Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
    Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy.
    Murphy BA; Motzer RJ; Mazumdar M; Vlamis V; Nisselbaum J; Bajorin D; Bosl GJ
    Cancer; 1994 May; 73(10):2520-6. PubMed ID: 7513603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In which marker-positive patients with germ cell tumors is residual tumor resection of value?].
    Weinknecht S; Hartmann M; Weissbach L
    Urologe A; 1998 Nov; 37(6):621-4. PubMed ID: 9887490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-radiation chemotherapy with response-based radiation therapy in children with central nervous system germ cell tumors: a report from the Children's Oncology Group.
    Kretschmar C; Kleinberg L; Greenberg M; Burger P; Holmes E; Wharam M
    Pediatr Blood Cancer; 2007 Mar; 48(3):285-91. PubMed ID: 16598761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic difficulties before definitive treatment of an extragonadal retroperitoneal germ cell tumor.
    Lassmann J; Wille A; Wiechen K; Taupitz M; Loening SA
    Urology; 2001 Aug; 58(2):281. PubMed ID: 11489725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group.
    Aparicio J; Sánchez-Muñoz A; Ochenduszko S; Gumà J; Fernández-Aramburo A; García Del Muro X; Quiroga V; Sastre J; Alonso-Gordoa T; Sagastibelza N; Maroto P; Gómez de Liaño A; Vázquez S; Diz P; Durán I; Domenech M; Pinto A; Hernández A; González-Billalabeitia E; Terrasa J
    J Urol; 2019 Oct; 202(4):742-747. PubMed ID: 31163007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy of extragonadal germ cell tumors.
    Logothetis CJ; Samuels ML; Selig DE; Dexeus FH; Johnson DE; Swanson DA; von Eschenbach AC
    J Clin Oncol; 1985 Mar; 3(3):316-25. PubMed ID: 2579212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy.
    Eastham JA; Wilson TG; Russell C; Ahlering TE; Skinner DG
    Urology; 1994 Jan; 43(1):74-80. PubMed ID: 7506856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors for the histologic nature of residual tumor mass after chemotherapy in patients with advanced testicular cancer.
    Matsuyama H; Yamamoto N; Sakatoku J; Suga A; Hayashida S; Kamiryo Y; Nagata K; Naito K
    Urology; 1994 Sep; 44(3):392-8; discussion 398-9. PubMed ID: 8073552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin, etoposide, bleomycin first-line therapy and early resection of residual tumor in far-advanced germinal testis cancer.
    Pizzocaro G; Piva L; Salvioni R; Zanoni F; Milani A
    Cancer; 1985 Nov; 56(10):2411-5. PubMed ID: 2412683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BOP/VIP--a new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours.
    Lewis CR; Fossà SD; Mead G; ten Bokkel Huinink W; Harding MJ; Mill L; Paul J; Jones WG; Rodenburg CJ; Cantwell B
    Ann Oncol; 1991 Mar; 2(3):203-11. PubMed ID: 1710482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostatic metastases from testicular nonseminomatous germ cell cancer: two case reports and a review of the literature.
    Torelli T; Lughezzani G; Catanzaro M; Nicolai N; Colecchia M; Biasoni D; Piva L; Maffezzini M; Stagni S; Necchi A; Giannatempo P; Farè E; Salvioni R
    Tumori; 2013; 99(5):e203-7. PubMed ID: 24362870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors in metastatic nonseminomatous germ cell tumours.
    Hanson PR; Belitsky P; Millard OH; Lannon SG
    Can J Surg; 1993 Dec; 36(6):537-40. PubMed ID: 7504978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors?
    Gerl A; Lamerz R; Clemm C; Mann K; Hartenstein R; Wilmanns W
    Clin Cancer Res; 1996 Sep; 2(9):1565-70. PubMed ID: 9816334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.